TD-0212 TFA is an orally active dual pharmacology angiotensin II type 1 receptor (AT 1 ) antagonist and neprilysin (NEP) inhibitor, with a pK i of 8.9 for AT 1 and a pIC 50 of 9.2 for NEP
In Vitro
TD-0212 provides the enhanced activity of dual AT1/NEP inhibition with a potentially lower risk of angioedema relative to dual ACE/NEP inhibition. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
TD-0212 produces blood pressure reductions similar to omapatrilat and combinations of AT1 receptor antagonists and NEP inhibitors in models of renin-dependent and -independent hypertension . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:pKi: 8.9 (AT 1 ) pIC50: 9.2 (NEP)
规格
别名
TD-0212 三氟乙酸
规格或纯度
≥98%
英文名称
TD-0212 TFA
生化机理
TD-0212 TFA 是一种口服活性双药理学血管紧张素 II 1 型受体(AT 1 )拮抗剂和肾素酶(NEP)抑制剂,对 AT 1 的 pK i 为 8.9,对 NEP 的 pIC 50 为 9.2。